Bristol-Myers Squibb Company (BMY) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Drug Manufacturers - General
Is Bristol-Myers Squibb Company a safe investment right now?
Bristol-Myers Squibb Company's Altman Z-Score of 1.74 places it in the distress zone. Our DCF model estimates intrinsic value at $79.46, suggesting the stock may be undervalued by 26%. Moat rating: 2.0/5 stars.
Could Bristol-Myers Squibb Company go bankrupt? Altman Z-Score analysis
Z-Score of 1.74 falls below the 1.8 distress threshold, indicating significant financial stress.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives BMY's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.0649 | 1.2 | 0.08 |
| B · Retained Earnings / Total Assets | RE / TA | 0.161 | 1.4 | 0.23 |
| C · EBIT / Total Assets | EBIT / TA | 0 | 3.3 | 0.0 |
| D · Market Cap / Total Liabilities | MCap / TL | 1.584 | 0.6 | 0.95 |
| E · Revenue / Total Assets | Rev / TA | 0.486 | 1.0 | 0.49 |
How has BMY's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2016 | 5.59 | Safe |
| 2017 | 5.83 | Safe |
| 2018 | 5.44 | Safe |
| 2019 | 5.8 | Safe |
| 2020 | 3.34 | Safe |
| 2021 | 1.48 | Distress |
| 2022 | 1.81 | Gray |
| 2023 | 2.02 | Gray |
| 2024 | 2.13 | Gray |
| 2025 | 1.74 | Distress |
Source: Calculated from BMY's latest 10-K filing on SEC EDGAR.
What is Bristol-Myers Squibb Company actually worth?
Fair value range: $58.55 — $120.17
Valuation Methods
| Method | Fair Value | Weight | Detail |
|---|---|---|---|
| Historical PE × Forward EPS | $63.39 | 50% | 14.0x avg PE (3 years) × $4.53 forward EPS |
| DCF (Discounted Cash Flow) | $120.17 | 30% | Two-stage DCF: $11.1B TTM FCF, 4.3% growth, 7.0% WACC |
| EV/FCF Multiple | $58.55 | 20% | TTM FCF × 14x multiple + net cash |
Assumptions & Data Sources
| Parameter | Value | Source |
|---|---|---|
| FCF Growth Rate (Stage 1) | 4.3% | 70% analyst consensus + 30% historical |
| Analyst EPS Growth (This Year) | 1.9% | Consensus (25 analysts) |
| Analyst EPS Growth (Next Year) | -2.1% | Consensus |
| Historical 5Y FCF CAGR | 14.4% | SEC EDGAR |
| Terminal Growth Rate | 2.5% | Long-term GDP proxy |
| Discount Rate (WACC) | 7.0% | CAPM (Rf=4.3% + 0.5*5.5%) |
| Net Cash / (Debt) | $-36,514M | Balance sheet |
| Base FCF (TTM) | $11.1B | Trailing 12 months |
| Shares Outstanding | 2,041,735,455 | Latest |
Sensitivity Analysis
| Growth Rate | 8% WACC | 10% WACC | 7.0% WACC | 13% WACC |
|---|---|---|---|---|
| 0% | $87.89 | $64.95 | $106.97 | $46.86 |
| 2.5% | $101.75 | $74.61 | $124.36 | $53.30 |
| 5.0% | $117.65 | $85.66 | $144.34 | $60.60 |
| 7.5% | $139.34 | $100.48 | $171.85 | $70.19 |
Free Cash Flow History
| Year | FCF | Growth |
|---|---|---|
| 2016 | $2.6B | — |
| 2017 | $1.3B | +-51.0% |
| 2018 | $1.8B | +43.4% |
| 2019 | $4.2B | +129.0% |
| 2020 | $6.1B | +44.9% |
| 2021 | $7.4B | +20.6% |
| 2022 | $13.3B | +80.3% |
| 2023 | $15.2B | +14.5% |
| 2024 | $11.9B | +-21.6% |
| 2025 | $12.7B | +5.9% |
Source: FCF data from SEC EDGAR filings. Price via Yahoo Finance.
Does Bristol-Myers Squibb Company have a durable competitive advantage?
Moat rating: 2.0/5.
What makes up BMY's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 1/5.
How stable is BMY's return on invested capital?
No ROIC history available.
| Year | ROIC | Trend |
|---|
Source: ROIC calculated from SEC EDGAR filings.
Is Bristol-Myers Squibb Company's dividend safe?
Can Bristol-Myers Squibb Company afford its dividend?
Payout ratio is 72.0%. FCF covers the dividend 2.8x. 55 consecutive years of payments.
Bristol-Myers Squibb Company's key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $45.0B | $46.2B | $42.5B | Rising |
| Net Income | $8.0B | $6.3B | −$9.0B | Rising |
| Free Cash Flow | $12.7B | $11.9B | $13.3B | Stable |
| Gross Margin | 18.2% | 17.5% | N/A | — |
Common questions about Bristol-Myers Squibb Company
Is Bristol-Myers Squibb Company at risk of going bankrupt?
Bristol-Myers Squibb Company's Altman Z-Score of 1.74 places it in the distress zone. This metric uses balance sheet ratios to predict bankruptcy probability within 2 years. A score below 1.8 signals distress, while above 3.0 indicates safety.
What is Bristol-Myers Squibb Company's intrinsic value based on DCF?
Our DCF model estimates Bristol-Myers Squibb Company's intrinsic value at $79.46 per share. The current margin of safety is 25.6%. This estimate is based on historical free cash flow trends and a risk-adjusted discount rate.
Does Bristol-Myers Squibb Company have a competitive moat?
Bristol-Myers Squibb Company receives a moat rating of 2.0 out of 5 stars, based on ROIC stability, gross margin trends, and estimated switching costs. A rating above 3.5 suggests a durable competitive advantage.
Is Bristol-Myers Squibb Company's dividend safe?
Our dividend safety analysis examines payout ratio, free cash flow coverage, and the company's streak of consecutive dividend payments to determine whether the current payout is sustainable.
Before you invest in Bristol-Myers Squibb Company, make sure you truly understand it.
A deep understanding of a company's fundamentals, risk profile, and competitive position dramatically increases your investment accuracy and odds of success.
Pass the quiz to earn the BMY Certified Value Investor badge.
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 20, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
BMY analysis methodology: How we calculate fair value, Z-Scores, and moat ratings